Company: RNAC
Filing Date: 2025-06-16
Form Type: 8-K
Source: 0001453687-25-000093
Chunk: 0

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-06-16
Form: 8-K
Item: Item 5.07
Chunk 0
---
Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 13, 2025, Cartesian Therapeutics, Inc. (the “ Company”) held the 2025 Annual Meeting of Stockholders (the “ Annual Meeting”). A total of 21,868,804 shares of the Company’s common stock, par value $0.0001 per share (the “common stock”), were present electronically or represented by proxy at the meeting, representing approximately 84.31% of the Company’s outstanding common stock as of the April 14, 2025 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Proxy Statement.

Proposal 1 - Election of three Class III Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.

  NOMINEE                                Votes FOR      Votes WITHHELD      Broker Non-Votes  
 ──────────────────────────────────────────────────────────────────────────────────────────────
  Timothy C. Barabe, M. B. A.           19,208,637             651,344             2,008,823  
  Carsten Brunn, Ph. D.                 19,841,557              18,424             2,008,823  
  Nishan de Silva, M. D., M. B. A.      19,840,306              19,675             2,008,823  

Based on the votes set forth above, each director nominee was duly elected to serve until the Company’s 2028 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.

Proposal 2 - Approval, on a non-binding and advisory basis, of a resolution approving the compensation of the Company’s named executive officers.

   Votes FOR      Votes AGAINST      Votes ABSTAINED      Broker Non-Votes  
 ────────────────────────────────────────────────────────────────────────────
  19,701,123            157,132                1,726             2,008,823  

Based on the votes set forth above, the stockholders approved, on a non-binding and advisory basis, a resolution approving the compensation of our named executive officers.

Proposal 3 - Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025.